Niox Group PLC
LSE:NIOX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Niox Group PLC
LSE:NIOX
|
UK |
|
M
|
MR. D.I.Y. Holding (Thailand) PCL
SET:MRDIYT
|
TH |
|
Surgical Science Sweden AB
OTC:SUSRF
|
SE |
|
P
|
Pacifico Renewables Yield AG
XETRA:PRY
|
DE |
|
H
|
Hunan Nucien Pharmaceutical Co Ltd
SSE:688189
|
CN |
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
US |
|
Z
|
Zhejiang JW Precision Machinery Co Ltd
SZSE:300984
|
CN |
|
Shenzhen Energy Group Co Ltd
SZSE:000027
|
CN |
|
E
|
Enel Americas SA
SGO:ENELAM
|
CL |
|
Zanyu Technology Group Co Ltd
SZSE:002637
|
CN |
|
Kenmare Resources PLC
LSE:KMR
|
IE |
|
O
|
Ober SA
PAR:ALOBR
|
FR |
|
CapitaLand Ascott Trust
OTC:ATTRF
|
SG |
|
Saudi Investment Bank SJSC
SAU:1030
|
SA |
Niox Group PLC
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.
